BioMarin Pharmaceutical, Inc. (NASDAQ:BMRN)

wishingwealth stock list Tue, Apr 23, 2013, 8 new high stocks w/good recent earnings and technicals TC2000 scan

You can dip your foot in the pool, but you can't have a swim

Since I bought this stock it has gone up 139% and keeps growing.

It has a niche position for research and development in rare ailments.

Tremendous pipeline of orphan drug candidates

The global target market for Morquio syndrome patients with ability to pay for treatment is around 2500 patients. ThinkEquity analyst Kimberly Lee estimates the market potential of GALNS at 575 million annually. This would be $230,000 annually per patient... It goes without saying that Kimberly's math skills are at a preschool level.

GALNS data coming up soon and the eternal buyout hype should keep it going up

porto.likedded it.

IBD EPS, RS, SPROE, Acc ratings plus P/E and div yield
MED 7 89 EB NEG

Value of omega 3 fatty acids from ocean getting greater recognition. Efficient extraction process

Up Up and away

Good pipeline. Filling niches where big pharma isn't interested in going. Solid front office leadership

A Director resigned today because his industry contacts led him to find out the CEO hid from the Board a purchase offer. This is the size of company that many others could purchase in order to get its intellectual property.

i usually don't by based soley on a recommendation without researching it my self, but I did this one. probably a mistake?

Three approved drugs which are all classified as orphan drugs make this a slightly profitable company. Pipeline is a few years out so look for them to try to make a near term acquisition or be taken out themselves.

With the economy coming back and baby boomers getting older, this company should do very well.

Pharmaceutical companies should remain strong, even with a relatively high P/E I still like its chances in the next year.

A rising star following GENZ. Good deal with LJPC recently on lupus drug.

Has a good position in the market for drugs that can help people.